Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cogent Biosciences Inc COGT

Healthcare Biotechnology
Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Company’s clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3Ka. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.


NDAQ:COGT - Post by User

Cogent Biosciences Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(88)
•••
Post by whytestockson Feb 14, 2024 10:15am
19 Views
Post# 35879598

Cogent Biosciences Reports Oversubscribed $225M PP

Cogent Biosciences Reports Oversubscribed $225M PP
Just In: $COGT Cogent Biosciences Reports Oversubscribed $225M PP2024-02-14 09:31:30 ET DENVER, Colo., Feb. 14, 2024 ( www.247marketnews.com )- Cogent Biosciences, Inc.&#x202F; (NASDAQ: COGT ) reported, this morning, that it entered into a securities purchase agreement for a private investment in public equity financing in which Cogent will sell ...COGT - Cogent Biosciences Reports Oversubscribed $225M PP

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities